Article
Probiotic therapy with Saccharomyces boulardii for heart failure patients: A randomized, double-blind, placebo-controlled pilot trial
Registro en:
COSTANZA, Annelise C. et al. Probiotic therapy with Saccharomyces boulardii for heart failure patients: A randomized, double-blind, placebo-controlled pilot trial. International Journal of Cardiology, v.179, p.348–350, 2015.
0167-5273
10.1016/j.ijcard.2014.11.034
Autor
Costanza, Annelise C
Moscavitch, Samuel D
Faria Neto, Hugo C. C
Mesquita, Evandro T
Resumen
On the last decade, there has been a progressive increase in a number of publications on microbiota and therapeutic potential of probiotics. Recent studies have been suggesting that consuming probiotics may have benefits on cardiovascular system, as the improvement on blood pressure control by a modest degree [1]. Heart failure (HF) patients present low grade inflammation that participates on the progression of cardiac remodeling [2]. Moreover, when the heart is failing, myocytes show enhanced expression of inflammatory mediators, as adhesion molecules, tumor necrosis factor (TNF)-a, interleukin-6 and others [2]. Jan. 2016